Skip to content

Genetic Modifiers for 22q11.2 Syndrome

Genetic Modifiers for 22q11.2 Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00916955
Acronym
VCFS
Enrollment
Unknown
Registered
2009-06-10
Start date
2008-03-31
Completion date
2015-02-28
Last updated
2021-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

22q11.2 Deletion Syndrome

Keywords

22q11.2 deletion syndrome, velo-cardio-facial syndrome, congenital anomalies, mental illness, congenital heart disease

Brief summary

The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.

Interventions

OTHERObservation

Observe development of syndrome over time

Sponsors

Albert Einstein College of Medicine
CollaboratorOTHER
State University of New York - Upstate Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* FISH confirmed diagnosis of 22q11.2 deletion syndrome

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
gene signal strength4 years

Secondary

MeasureTime frame
physical phenotype4 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026